Protein phosphorylation generates a source of phosphopeptides that are presented by major histocompatibility complex class I molecules and recognized by T cells. As deregulated phosphorylation is a hallmark of malignant transformation, the differential display of phosphopeptides on cancer cells provides an immunological signature of 'transformed self'. Here we demonstrate that phosphorylation can considerably increase peptide binding affinity for HLA-A2. To understand this, we solved crystal structures of four phosphopeptide-HLA-A2 complexes. These identified a novel peptide-binding motif centered on a solvent-exposed phosphate anchor. Our findings indicate that deregulated phosphorylation can create neoantigens by promoting binding to major histocompatibility complex molecules or by affecting the antigenic identity of presented epitopes. These results highlight the potential of phosphopeptides as novel targets for cancer immunotherapy.
Protein phosphorylation generates a source of phosphopeptides that are presented by major histocompatibility complex class I molecules and recognized by T cells. As deregulated phosphorylation is a hallmark of malignant transformation, the differential display of phosphopeptides on cancer cells provides an immunological signature of 'transformed self'. Here we demonstrate that phosphorylation can considerably increase peptide binding affinity for HLA-A2. To understand this, we solved crystal structures of four phosphopeptide-HLA-A2 complexes. These identified a novel peptide-binding motif centered on a solvent-exposed phosphate anchor. Our findings indicate that deregulated phosphorylation can create neoantigens by promoting binding to major histocompatibility complex molecules or by affecting the antigenic identity of presented epitopes. These results highlight the potential of phosphopeptides as novel targets for cancer immunotherapy.
Major histocompatibility complex (MHC) class I molecules serve a critical function in immunity by presenting at the cell surface a broad repertoire of peptides generated by proteasomal degradation of intracellular proteins 1 . Changes in protein expression or metabolism due to intracellular infection or cellular transformation modify the repertoire of peptides generated and therefore displayed by MHC class I molecules, which results in the presentation of 'altered self ' to the immune system. T cell receptor (TCR)-mediated recognition of specific MHC-bound peptides by CD8 T lymphocytes results in cytolytic activity and the release of proinflammatory cytokines, which are key components of antiviral and antitumor immunity. Evidence suggests that peptides containing post-translational modifications, including deamidation, cysteinylation, glycosylation and phosphorylation, contribute to the pool of MHC-bound peptides presented at the cell surface and represent potential targets for T cell recognition 2 . Indeed, most naturally occurring peptides bearing post-translational modifications defined so far can be discriminated from their unmodified homologs specifically by T cells [2] [3] [4] . In some cases, quantitative and/ or qualitative changes in post-translational modification that occur during cellular transformation, infection and inflammation result in the display of new MHC-associated neoantigens 2 . MHC-associated peptides bearing post-translational modifications therefore have the potential to contribute to the repertoire of altered self antigens in a diverse range of cellular settings.
Studies have emphasized protein phosphorylation as a process with the ability to generate unique peptides bound to MHC class I molecules. Many different phosphorylated peptides (phosphopeptides) are presented by several HLA-A and HLA-B alleles that are prevalent in humans 3, 4 , which demonstrates their widespread potential as antigens. Moreover, CD8 + T lymphocytes recognize these phosphopeptides in a way that is both specific for the peptide sequence and dependent on the phosphate 3, 4 . Thus, phosphorylated peptides can be immunologically distinguished from their nonphosphorylated counterparts. Consistent with their presentation by MHC class I molecules, most phosphopeptides are derived from proteins that function intracellularly, and processing of both model and naturally occurring phosphopeptides is dependent on transport into the endoplasmic reticulum by the transporter associated with antigen processing 3, 5 . Furthermore, rapid degradation by the proteasome, a process that regulates the activity of many transcription factors, cell growth modulators, signal transducers and cell cycle proteins [6] [7] [8] , often depends on phosphorylation of the target protein [9] [10] [11] . Many MHC class I-bound phosphopeptides contain previously identified phosphorylation sites, and most of the proteins from which these peptides are derived are known to be phosphorylated by established cellular signaling pathways 3, 4 . Collectively, these observations suggest that MHC class I-bound phosphopeptides arise from the regulated degradation of folded and functional phosphoproteins rather than of defective ribosomal translation products 12 .
Phosphopeptide antigens are of considerable therapeutic interest because deregulation of protein kinase activity, normally tightly controlled, is one of the hallmarks of malignant transformation and is thought to contribute directly to oncogenic signaling pathways involved in cell growth, differentiation and survival [13] [14] [15] . In addition, mutation-induced deregulation of a limited number of critical kinases can often lead to the activation of several signaling cascades and increases in the extent of protein phosphorylation in the cell [16] [17] [18] . These considerations suggest that alterations in protein phosphorylation during malignancy represent a distinctive immunological signature of 'transformed self' . Consistent with that idea, the phosphopeptides presented by HLA-A*0201 (called 'HLA-A2' here) that have been identified so far include those derived from proteins involved in cell cycle-regulation and oncogenic-signaling pathways, and many are differentially expressed by MHC class I molecules on different tumor cell lines 4 . Consequently, MHC class I-bound phosphopeptides represent a new set of target antigens for cancer immunotherapy, and their recognition by CD8 + T lymphocytes might also contribute to antitumor immunity. Understanding the molecular aspects of phosphopeptide presentation is needed to facilitate cancer therapies targeting phosphopeptides and is therefore a major goal. Here we combined peptide-MHC binding studies with crystallographic approaches and bioinformatics methods to investigate the molecular basis of phosphopeptide presentation by HLA-A2. Our results show the critical influence that phosphorylation can exert on peptide-MHC binding and antigen structure.
RESULTS

Unusual characteristics of HLA-A2-bound phosphopeptides
Published work has identified 37 phosphopeptides presented at the surface of transformed cell lines by the human MHC class I molecule HLA-A2. Each of these phosphopeptides is 9-13 amino acids in length (a range similar to that of nonphosphorylated HLA-A2 peptides) and contains a single phosphorylated serine residue (p-Ser) or phosphorylated threonine residue (p-Thr) 4 . Examination of this set of phosphopeptides identified several unusual features. First, although p-Ser or p-Thr residues were located at positions 3-9 (P3-P9), 68% were at P4 (Fig. 1a and Supplementary Table 1 online) . Second, 62% of the phosphopeptides had a positively charged amino acid (arginine or lysine) at P1; in contrast, only 9-12% of nonphosphorylated HLA-A2 epitopes derived from either the Immune Epitope database or a set of naturally processed peptides extracted from B lymphoblastoid cells had a positively charged amino acid at this position ( Fig. 1b and Supplementary Table 1) .
To test whether the features noted above might reflect a confluence of motifs required for binding to HLA-A2 and to protein kinases, we generated data sets of predicted HLA-A2-binding peptides from identified human p-Ser phosphorylation sites in the databases of PhosphoSites and the European Molecular Biology Laboratory 19, 20 . However, the phosphorylation sites of the peptides in these data sets were distributed evenly among all peptide positions, with no P4 bias ( Fig. 1a and Supplementary Table 1 ). In addition, in the subset of those predicted peptides with p-Ser at P4, only 23% had an arginine or lysine residue at P1 (Fig. 1b and Supplementary Table 1 ). Finally, although there was no difference between the phosphopeptides and either of the two nonphosphorylated peptide data sets in the representation of P9 carboxy-terminal residues, 49% of the phosphopeptides had subdominant anchor residues (methionine, threonine, glutamine or valine instead of leucine) at P2, compared with only 16-19% of nonphosphorylated peptides (P o 0.001; Fig. 1c,d and Supplementary Table 1) . Collectively, these distinct features suggested either an unusual selection of the phosphopeptide repertoire by the antigen-processing machinery or an unusual MHC-peptide binding interaction.
To determine how phosphorylation affected the interaction of peptides with MHC molecules, we evaluated the binding of P2 and PC anchor residues are in bold; positively charged P1 residues are underlined. Data are representative of four independent assays, with various peptides assayed one to four times.
several phosphopeptides and their nonphosphorylated counterparts to purified HLA-A2 molecules. Notably, the affinities of most phosphopeptides were much greater than those of their nonphosphorylated counterparts ( Table 1 ). This effect was most prominent among the peptides phosphorylated at P4; phosphorylation at P5 or P8 exerted little influence on HLA-A2 binding affinity. The largest phosphorylation-related increases in affinity were in the subset of peptides that also had an arginine residue at P1 and subdominant P2 and/or carboxy-terminal (PC) anchor residues. In their nonphosphorylated form, many of these peptides showed very low binding affinities, which suggested that they might be absent from the cell surface or underrepresented relative to their phosphorylated counterparts. Consistent with those observations, only 23% of the HLA-A2-restricted phosphopeptides had a score of above 100 with the epitope-prediction algorithm of the Bioinformatics and Molecular Analysis Section of the National Institutes of Health, compared with 52% of the naturally processed nonphosphorylated peptides extracted from B lymphoblastoid cells (P ¼ 0.0026; Supplementary Table 2 online). Similarly, the SYFPEITHI algorithm predicted the HLA-A2 binding of only 67% of phosphorylated peptides versus 83% of nonphosphorylated peptides (P ¼ 0.0179). Overall, these results demonstrate a direct effect of the phosphate moiety on the binding of peptide to HLA-A2 and suggest that the skewed distribution of P1 and P2 residues among phosphopeptides is related to this effect.
Phosphate-mediated phosphopeptide and HLA-A2 contacts
To understand the molecular basis of phosphopeptide presentation, we determined the crystal structures of four phosphopeptides in complex with HLA-A2. The peptides consisted of one nonamer (RQApSLSISV (PKD2)) and three decamers (RTYpSGPMNKV (RTY), RQApSIELPSM (RQA_M) and KMDpSFLDMQL (KMD), where 'pS' indicates a phosphorylated serine residue and the designations in parentheses after the sequences are the peptide identifiers) and were derived from four different proteins. Each was phosphorylated at P4, either arginine or lysine at P1, and had subdominant anchor residues at P2 and, in some cases, PC. We solved these structures to a resolution of 1.6-2.2 Å by molecular replacement (Supplementary Table 3 online), which allowed detailed interpretation of the phosphopeptide structure and its interactions with the HLA-A2 molecule.
The structures resembled published MHC class I complexes involving nonphosphorylated peptides, with the peptide adopting an extended conformation 21 ( Fig. 2 and Supplementary Fig. 1 online). In addition, stabilizing interactions documented before between MHC residues and peptide termini were retained 22, 23 (Supplementary Table 4 online), and the P2 and PC anchor residues were oriented in a direction broadly similar to that of published HLA-A2 structures 22, 23 . Thus, phosphorylation at P4 permits association with the 'platform' formed by the a1-a2 domains of MHC class I molecules in a way that preserves many features of peptide-MHC interactions noted before. In all four complexes, the p-Ser residue at P4 was structurally conserved and was oriented upward and toward the amino terminus of the phosphopeptide (Figs. 2d and 3a and Supplementary Table 5 online). P4 p-Ser residues were solvent exposed, were located in a prominent section of each peptide and therefore were available for direct contact with the TCR. In contrast, in HLA-A2 structures presenting nonphosphorylated peptides, the P4 side chain adopted a variety of orientations, including pointing toward the a1 or a2 helices or straight upward 22 (Fig. 3a) . Notably, the conserved position of the negatively charged p-Ser residue allowed it to form multiple stabilizing interactions with nearby MHC residues (Fig. 3b,c and Supplementary Table 5 ). In the three structures with arginine at P1, electrostatic contacts with the a1 domain were mediated by the arginine residue at position 65 (Arg65), which protruded from the top of the a1 helix and contacted the p-Ser O2P atom, whereas Lys66, located nearer the base of the helix, contacted O1P (Fig. 3b) . Similar interactions were maintained in the structure with a lysine residue at P1, although a subtle reorientation of the phosphate moiety eliminated the contact of p-Ser with Arg65 but permitted an additional compensatory contact with Lys66 (Fig. 3c) . Furthermore, the arginine and lysine residues at P1 also had an upward orientation and mediated bridging contacts between p-Ser and the a2 helix. These included many hydrophobic interactions between the P1 side chain and Trp167, and electrostatic contacts with the p-Ser O1P atom. In addition, in all phosphopeptides except KMD, the p-Ser was further stabilized by a conserved ordered water molecule that formed bridging hydrogen-bonding interactions to the p-Ser O g atom, the P2 carbonyl group and the P1 arginine residue. Notably, these conserved p-Ser phosphate moiety interactions seemed to constrain the phosphopeptide main chain at P4, and consequently, the diversity in length of the phosphopeptides studied here was accommodated by differences between P5 and PC in the main-chain conformations adopted (Fig. 3a) . Thus, for peptides phosphorylated at P4, the phosphate forms an integral part of the structure, bridging the a1 and a2 helices and providing a focal point for a conserved network of stabilizing interactions with the MHC molecule.
Subdominant anchor interactions are structurally suboptimal
The observation that subdominant primary anchor residues were overrepresented in phosphopeptides and/or were associated with phosphate-enhanced MHC binding was consistent with the hypothesis that phosphate-mediated contacts compensated for suboptimal interactions between anchor residues and their binding pockets in HLA-A2. To evaluate this issue directly, we determined how these subdominant anchor residues were accommodated in the phosphopeptide-HLA-A2 complexes. Studies have established that dominant P2 leucine anchor residues fill the B pocket optimally, providing hydrophobic interactions with Phe9, Met45 and Val67 (refs. 22,23; Fig. 4a ). In the four phosphopeptide-HLA-A2 structures, the subdominant methionine, threonine and glutamine P2 residues occupied the B pocket in an overall orientation similar to that of leucine ( Fig. 4b-d and Supplementary Table 6 online). However, whereas methionine formed interactions with B-pocket residues similar to those formed by leucine, the smaller threonine side chain completely eliminated these contacts and showed minimal compensatory interactions ( Fig. 4c and Supplementary Table 6 ). Accommodation of the polar glutamine residue in the mainly hydrophobic B pocket resulted in a highly unusual set of direct and water-mediated interactions with neighboring residues (Fig. 4d and Supplementary Tables 6 and 7 online). The formation of this set of interactions was associated with displacement of His70, a residue positionally highly conserved in other HLA-A2 structures, by ordered water molecules; this displacement resulted in substantial reshaping of the B-pocket surface. At the PC, the lengthy methinoine side chain of the RQA_M phosphopeptide permitted van der Waals contacts in the F pocket that were similar to those of dominant anchors. However, stabilizing interactions between the phosphopeptide main chain and MHC evident when valine or leucine anchor residues were present were disrupted, as accommodation of methionine necessitated a substantial elevation of the main chain, which resulted in loss of hydrogen bonds between MHC residues and the peptide main chain adjacent to its carboxyl terminus (Fig. 4e,f and Supplementary Table 8 online) . Thus, several of the subdominant anchor residues tolerated in the presence of phosphate-mediated contacts result in structurally suboptimal interactions with the HLA-A2 heavy chain. These include fewer or unusual stabilizing interactions and compensatory conformational changes in surrounding pocket residues or the peptide itself. Such changes would be expected to incur energetic penalties 24, 25 relative to dominant anchor interactions, but in the phosphorylated forms of these epitopes, we hypothesized that these penalties would be offset by phosphate-mediated contacts with the MHC class I molecule. Indeed, the electrostatic nature of the phosphate-mediated contacts and the fact that they involved solvent-exposed elements of the phosphopeptide-MHC complex suggested the phosphate moiety acts as a novel 'surface anchor residue' (Fig. 5) .
Energetic basis of phosphopeptide binding to HLA-A2
The fact that phosphate-mediated contacts involve oppositely charged residues and can occur in the presence of such suboptimal anchor residue interactions suggested they may provide substantial contributions to the affinity of phosphopeptides for HLA-A2 (ref. 26 ). To directly test this hypothesis, we evaluated the HLA-A2-binding affinity of variants of the phosphopeptide RQApSIELPSM. The HLA-A2-binding affinity of the phosphorylated peptide was 150-fold higher than that of the nonphosphorylated peptide ( Table 2) . Although still somewhat lower than that resulting from substitution of optimal anchor residues at the P2 and PC positions in the nonphosphorylated peptide, the half-maximal inhibitory concentration (IC 50 ) of the phosphopeptide was in the range considered 'high' 27 . Notably, substitution of alanine for arginine at P1 led to only a modest fivefold decrease in HLA-A2-binding affinity of the phosphopeptide. We also evaluated the interaction of these peptides with a mutant HLA-A2 molecule containing a substitution of alanine for the arginine at position 65 (HLA-A2-R65A). The phosphopeptide also bound to this molecule with a high affinity only marginally weaker than its affinity for wild-type HLA-A2, and removal of the phosphate led to binding of much lower affinity ( Table 2) . Notably, however, a phosphopeptide containing an alanine residue at P1 showed a low binding affinity for HLA-A2-R65A, similar to that of the unphosphorylated species, and much less than its affinity for wild-type HLA-A2 ( Table 2 ). The modest effect of single substitutions at P1 or HLA-A2-R65A may result from reorientation of the p-Ser moiety (as noted for KMD, with elimination of the Arg65 interaction), which could increase the energetic contribution of the remaining interaction. These data confirm the energetic importance of interactions noted in the crystal structures, demonstrating that the P4 phosphate serves a key function in the binding of a peptide to HLA-A2 through its interaction with both the peptide P1 arginine residue and Arg65 in the a1 helix.
Effect of the phosphate moiety on TCR recognition
The solvent-exposed and prominent nature of the phosphate in the phosphopeptide-HLA-A2 complexes we studied suggested that, in addition to affecting MHC binding, the phosphate moiety might also affect interaction with the TCR. To address that possibility, we superimposed previously determined TCR-HLA-A2 complexes onto the phosphopeptide-HLA-A2 structures. This analysis indicated close proximity of the complementarity-determining region 3a (CDR3a) loop to the phosphate (Fig. 6) , which suggested that direct recognition of the phosphate moiety by the TCR probably occurs. In contrast, the Figure 6 Potential influence of the phosphate moiety on antigenic identity. (a) Left, superposition of the B7 human TCR-HLA-A2 structure (khaki, V a ; red, V b ) onto the PKD2 complex, based on superposition of the a1-a2 platforms. Gray, MHC heavy chain; cyan, b 2 -microglobulin; blue, PKD2, including the P4 p-Ser side chain. Middle, overlay of CDR3 loops of the A6, B7 and JM22 TCRs onto the PKD2-HLA-A2 complex (Protein Data Bank accession codes: 1AO7 (green, A6 CDR3a; pink, CDR3b); 1BD2 (yellow, B7 CDR3a; red, CDR3b); 1OGA (cyan, JM22 CDR3a; purple, CDR3b)). Red spheres, a1 and a2 helix residues contacted by CDR1 and CDR2 loops of these TCRs. Right, proximity of CDR3a loops to the p-Ser phosphate (green, A6; yellow, B7; cyan, JM22). Gray, MHC heavy chain; blue, PKD2 phosphopeptide main chain; red and pink, p-Ser phosphate V a and V b , variable a-and b-domains of the TCR. (b) Main-chain conformation around P4 in phosphorylated (red) and nonphosphorylated (gray) peptides (Protein Data Bank accession codes: 1HHG, 1HHH, 1HHJ, 1T21, 2BSU and 2CLR). Criteria for nonphosphorylated structures were dominant anchor residues and non-glycine residues at P3-P5. Superpositions were based on Ca atoms of P1-P3. The mean distance of the phosphopeptide P4 Ca from the P4 Ca position of RQA_M was 0.38 (range, 0.1-0.5 ), whereas that of the nonphosphorylated peptides was 1.09 (range, 0.3-2.3).
CDR3b loops lie adjacent to central and carboxy-terminal sections of the peptide. In addition, to address whether phosphorylation might affect TCR interaction indirectly by altering the conformation of phosphorylated peptides relative to their nonphosphorylated counterparts, we aligned the a-carbon backbones of the structures presented here with those of several other HLA-A2-associated peptides. Notably, this analysis suggested that phosphorylation may constrain the peptide main chain at P4 (Fig. 6b) , which could result in conformational differences between phosphopeptides and their nonphosphorylated counterparts in the P5-PC region.
DISCUSSION
Our results here have provided structural and energetic insights into the presentation of phosphopeptides by MHC class I molecules. They outline a molecular mechanism whereby phosphorylation can enhance the stability of a peptide-MHC association and in doing so identify a canonical phosphopeptide-binding motif defined by a P4 phosphate moiety and a positively charged P1 side chain. In combination, these two features allow a set of interactions that link key elements of MHC class I secondary structure; phosphopeptides with this canonical motif engage in direct phosphate-mediated contacts with the MHC a1 helix (Arg65 or Lys66) and, through electrostatic contacts with the P1 side chain, indirect contacts with the a2 helix (Trp167). In all structures we described with an arginine at P1, the position of the P4 phosphate moiety was highly conserved. Its altered position in the structure with a lysine at P1 shows that there is a degree of structural plasticity in this binding mode. It is unclear whether the difference in the P4 phosphate moiety position is related to the presence of arginine or lysine at P1 or is epitope specific. Regardless of which is true, the essential features, direct phosphate-mediated contacts with HLA-A2 a1 residues and indirect phosphate-mediated contacts with HLA-A2 a2 through the P1 side chain, were preserved in all structures. Notably, the binding energy engendered by the presence of the phosphate can be equivalent to that of a dominant primary anchor residue and can compensate for suboptimal B-and F-pocket interactions. However, structurally, the interaction of the phosphate moiety with HLA-A2 represents a departure from all MHC class I anchor residues described before, as it is not based on the insertion of an amino acid side chain into a pocket in the floor of the peptide-binding cleft but instead is based on interactions with the solvent-exposed surface of the peptide-MHC complex. This leads us to propose the term 'phosphate surface anchor' to describe this interaction.
Our results suggest that for some phosphopeptides, phosphateenhanced binding may be dominant in determining whether or not a specific peptide sequence is presented at the cell surface. In other cases, the effect of phosphorylation is more modest but may still lead to enhanced surface presentation. The ability of the phosphate surface anchor in the context of the canonical binding motif to enhance the binding of peptides with suboptimal conventional anchor residues probably broadens the total repertoire of phosphopeptides displayed by HLA-A2. Most notably, in the context of deregulated phosphorylation in cancer cells, phosphate-enhanced binding should allow the display of entirely new peptide antigens at the cell surface. In keeping with this, the distinctive features of the phosphopeptide repertoire will necessitate the development of improved algorithms for the prediction of MHC class I-binding epitopes. Although the present database of phosphopeptide sequences is too small to modify existing algorithms with precision, we note that phosphopeptides contain subdominant anchors that have been associated before with at least permissive binding to HLA-A2. Thus, modifications to existing algorithms might include prediction of phosphorylation sites and a binding coefficient that takes into account the positive contribution of the phosphate, analogous to that of conventional anchor residues.
The energetic effects of phosphorylation on peptide-MHC binding that we have documented here could explain the prevalence of the canonical 'P1 arginine or lysine, P4 phosphate' motif in the HLA-A2-restricted phosphopeptide repertoire. This leads to the prediction that peptides phosphorylated at other positions would have fewer or no phosphate-dependent stabilizing interactions with the MHC molecule. The limited set of such peptides that we have identified and evaluated in peptide-MHC affinity assays showed no evidence of phosphorylation-enhanced binding, consistent with that hypothesis. In addition, we have solved the structure of a peptide phosphorylated at P5 and found no stabilizing interactions between the phosphate moiety and the MHC molecule (D.H. Stones et al., unpublished data). However, our results do not exclude the possibility that other steps in the antigen-processing pathway contribute to the prevalence of the canonical P1-P4 motif. In particular, little is known about the effect of phosphorylation on proteasomal processing or transport by the transporter associated with antigen processing; this is an area for further investigation. Nonetheless, in the only relevant study, introduction of nonphysiological phosphorylations into naturally occurring MHC class I epitopes had little effect on transport by the transporter associated with antigen processing 5 . Therefore, it is possible that effects of phosphorylation on peptide-MHC affinity are dominant in selection of this motif in the HLA-A2-restricted phosphopeptide repertoire.
The phosphate-based binding motif we have described is likely to be of general importance, as Trp167 (which interacts with the p-Ser phosphate moiety indirectly through contacts with the P1 side chain) is retained in most MHC class I molecules 23 , and the residues on the a1 helix (Arg65 and Lys66) that interact with the p-Ser phosphate moiety are conserved in a wide range of HLA-A alleles. Consistent with a broader relevance of this canonical motif, one of the phosphopeptides presented by HLA-A2 (RVApS, derived from insulin receptor substrate 2) is also presented by HLA-A*6802 (ref. 3) , which retains these three key amino acids. In addition, many epitopes conforming to this canonical 'P1 arginine or lysine, P4 phosphate' motif are presented by HLA-B molecules (such as HLA-B*0702) 3 . Although Arg65 and Lys66 are not conserved in these molecules (unlike Trp167), HLA-B molecules have positively charged residues located nearby that are not present in HLA-A molecules but could have similar functions. Thus, the binding mode we identified could also have relevance for the presentation of phosphopeptides by HLA-B molecules. As HLA-B molecules generally present a larger repertoire of phosphopeptides 3 , further structural studies to identify their mode of phosphopeptide presentation are of considerable interest.
Our study also has implications for how phosphopeptides are recognized by the TCR, an issue that is relevant to the therapeutic targeting of these antigens. The recognition of MHC class I-restricted phosphopeptides by CD8 + T cells is both specific for the peptide sequence and dependent on the phosphate 3, 4 . The structures presented here have demonstrated that the P4 phosphate moieties of such epitopes are solvent exposed and very prominent, and suggest they probably form a component of the recognition surface directly contacted by a TCR. In support of this possibility, superimposition of previously determined TCR-HLA-A2 complexes onto the phosphopeptide-HLA-A2 structures indicated close proximity of the CDR3a loop to the phosphate moiety, whereas the CDR3b loops lie adjacent to central and carboxy-terminal sections of the peptide, which show substantial structural differences in the phosphopeptides we have studied. These analyses most strongly support a model in which the recognition interface comprises coordinate TCR interactions with the phosphate moiety itself and with separate epitopespecific features that depend on peptide sequence and conformation. In contrast, alignment of the a-carbon backbones of the phosphopeptide structures presented here with those of several other HLA-A2-associated peptides suggests that phosphorylation may constrain the peptide main chain at P4. As this could result in conformational differences between phosphopeptides and their nonphosphorylated counterparts in the P5-PC region, it is possible that some TCRs specifically recognize phosphate-dependent conformational differences in this region without making direct contacts with the phosphate moiety. Thus, in the transformed state, deregulated phosphorylation may generate neoantigens by enhancing the binding of low-affinity peptides by MHC class I and also by affecting the antigenic identity of presented epitopes, with the phosphate either participating as a direct contact element for the TCR or potentially altering the conformation of the peptide relative to its unphosphorylated counterpart. The goal of future studies will be to understand these issues in greater detail and to exploit a molecular understanding of phosphopeptide presentation and recognition to improve cancer immunotherapy.
METHODS
Peptide data sets and bioinformatics analysis. A data set of naturally processed peptides associated with HLA-A2 was identified by tandem mass spectrometry. Peptides were isolated from 2.5 Â 10 10 JY cells (a human lymphoblastoid cell line) by immunoaffinity chromatography 28 and were fractionated by reverse-phase high-performance liquid chromatography on a C18 column (Higgins Analytical HAISIL 300 column; 2.1 mm (diameter) Â 40 mm (length) containing silica beads 5 mm in diameter with a pore size of 300 Å ). Peptides were eluted with a gradient of two solvents, 0.1% (vol/vol) trifluoroacetic acid in Nanopure water, and 0.085% (vol/vol) trifluoroacetic acid in 60% (vol/vol) acetonitrile and 40% (vol/vol) Nanopure water, flowing at a rate of 200 ml/min. Thirty peptide-containing fractions were collected at intervals of 1 min and each was then subjected to a second dimension of chromatography with an identical C18 column and a gradient of solvents composed of 0.1% (vol/vol) triethylamine in Nanopure water (adjusted to a pH of 6.5 with acetic acid to form triethylammonium acetate; solvent A), and 40% (vol/vol) solvent A and 60% (vol/vol) acetonitrile (solvent B), flowing at a rate of 200 ml/min. Twenty second-dimension fractions were collected from each first-dimension fraction at intervals of 1 min and then were acidified with 2 ml glacial acetic acid. Material corresponding to 2 Â 10 9 cell equivalents (10%) of every fifth fraction of the second-dimension 'runs' from two widely separated first-dimension fractions were pooled, were loaded onto a microcapillary C18 high-performance liquid chromatography column 29 assembled in-house, were derivatized on the column with N-hydroxysuccinimidyl 2-(3-pyridyl) propionate and then were gradient-eluted into a Thermo Finnigan LCQ Deca mass spectrometer as described 29 . All peptide-containing fractions were analyzed by this same approach. The resulting tandem mass spectrometry spectra of the derivatized peptides were used to search the nonredundant database of known human proteins at the National Center for Biotechnology Information with the SEQUEST algorithm. All peptides in the data set were identified with a crosscorrelation (Xcorr) score of over 3.0. A second data set of peptides known to bind to HLA-A2 was obtained from the Immune Epitope Database. For analysis, we used only the nonamer and decamer peptide sequences in these data sets. Two data sets of identified human phosphorylation sites were provided by P. Hornbeck 20 and F. Diella 19 . For analysis, these data sets were further limited to human sequences containing p-Ser residues. Each data set was subsequently analyzed by the generation of nonamers spanning each phosphorylation site with p-Ser at P1, P3, P4, P5, P6, P7 or P8. Predicted HLA-A2-binding phosphopeptides were identified among this set of nonamers as those for which P2 was a leucine reside and P9 was a leucine or valine residue. These data sets were analyzed for the frequency of p-Ser at each position and for the frequency of arginine and lysine residues at P1 among those peptides with p-Ser at the P4 position. For statistical analysis of the data, distributions were analyzed with the two-tailed chi-squared (w 2 ) test (Graphpad Prism v5). P values of less than 0.05 were considered statistically significant.
Peptide-MHC binding affinities. HLA-A2 and R65A heavy chains were expressed in Escherichia coli, were refolded with b 2 -microglobulin and the peptide NLVPMVATV, and were purified as described above. Competitive peptide-binding assays were done as described 30 . Test peptide concentrations covered a 100,000-fold range, and each concentration was assayed in triplicate. MHC-peptide complexes were captured on microplates coated with monoclonal antibody W6/32 (to human HLA) and washed, and radioactivity was quantified with a microscintillation counter. The concentration of test peptide that displaced 50% of the radiolabeled peptide (IC 50 ) was calculated. In these conditions (in which the concentration of the label is less than the concentration of MHC and the IC 50 is greater than or equal to the concentration of MHC), the IC 50 is a reasonable approximation of the dissociation constant 31 .
Production and crystallization of MHC class I. HLA-A2 heavy chain and b 2 -microglobulin were expressed separately in E. coli, were purified from inclusion bodies and were refolded together with synthetic peptide 32 . Refolded complexes were purified by size-exclusion chromatography and were concentrated. Crystallization conditions for the phosphopeptide-HLA-A2 complexes were identified by the vapor-diffusion method with a mosquito nanoliter crystallization robot (TTP Labtech). Hanging drops consisting of 100 nl protein sample and 100 nl reservoir solution were set up in 96-well plates and were equilibrated against 100 ml reservoir solution at 22 1C. A total of 288 conditions were tested with the Index screen (Hampton Research), Wizard screen (Emerald Biosystems) and JCSG-plus screen (Molecular Dimensions) at protein concentrations of 8-26 mg/ml. The most favorable conditions were optimized (Supplementary Table 3 ) with hanging drops of 1 ml plus 1 ml, which yielded large diffraction-quality crystals that typically grew to a size of 200 mm Â 200 mm Â 100 mm after 3-4 d.
X-ray data collection, structure solution and refinement. Phosphopeptide-HLA-A2 complex crystals were soaked in reservoir buffer containing increasing concentrations (5%, 10% and 15% (vol/vol)) of ethylene glycol as a cryoprotectant before being 'flash-cooled' at 100K in a stream of nitrogen gas (Oxford Cryosystems). X-ray data were collected to a resolution of 1.6-2.2 Å on an inhouse MicroMax 007HF microfocus rotating anode X-ray generator (Rigaku) with a Saturn charge-coupled device detector. The crystals belonged to the space group C2 (except KMD, which belonged to P2 1 ) with the unit cell parameters described in Supplementary Table 3 , consistent with the presence of one phosphopeptide-HLA-A2 complex in the asymmetric unit. Each data set was integrated, scaled and merged with programs of the XDS suite 33 . Complex structures were determined by molecular replacement with the molecular-replacement program MOLREP 34 using as the search model a previously determined HLA-A2 structure with peptide residues omitted to eliminate model bias. In each case, the molecular-replacement calculations yielded unambiguous rotation and translation function solutions.
The molecular models were refined with the CNS crystallography and nuclear magnetic resonance system 35 and the REFMAC5 program for the refinement of macromolecular structures 34 . The progress of refinement was verified by monitoring of the variation of the R free value 36 calculated from an independent set of reflections, which were set aside for cross-validation purposes. The models were subjected to several rounds of alternating simulated annealing and positional refinement followed by isotropic B factor refinement. After the initial round of refinement, the R factor and R free values converged to about 30% (decreased from about 43%) and about 32% (decreased from about 43%), respectively. Examination of the resulting electron-density maps showed unbiased features in the electron density (full sequence of each phosphopeptide), which confirmed the validity of the molecular replacement solution. The COOT molecular graphics application 37 was used for all model manipulations. Once the R factor values were below 30%, water molecules were included in the models if they appeared in maps of F o -F c (observed structure factor -calculated structure factor) contoured at over 3s and were within hydrogen-bonding distance to chemically acceptable groups. These water molecules were added in successive steps and were included in the subsequent refinement cycles. Calculation of simulated annealing electrondensity omit maps confirmed the assignment of each phosphopeptide ligand. The final refinement statistics are in Supplementary Table 3 . The quality of the final refined models was verified with the PROCHECK and WHATCHECK programs of the Collaborative Computation Program CCP4i suite 34 , which demonstrated that non-glycine residues were absent from the disallowed regions of the Ramachandran plot. Most residues were well defined in all structures, except for a few solvent-exposed side chains. Hydrogen bonding and van der Waals contacts were analyzed with the CONTACT program of the CCP4 suite 34 . Data collection and refinement statistics are in Supplementary  Table 3 . Structural figures were produced with the POVScript program for displaying molecular three-dimensional structures 38 and Swiss-PdbViewer modeling tool 39 and were rendered with the Persistence of Vision Raytracer (POV-Ray) tool for three-dimensional graphics, with molecular surfaces generated with the molecular surface display program GRASP 40 .
Accession codes. Research Collaboratory for Structural Bioinformatics Protein Data Bank: PKD2, 3BGM; RQA_M, 3BH8; RTY, 3BH9; KMD, 2BHB.
Note: Supplementary information is available on the Nature Immunology website.
